'%3e%3cpath%20id='s'%20d='M0,162.5%2022.041947,230.338137%20-35.664619,188.411863H35.664619L-22.041947,230.338137z'/%3e%3cuse%20xlink:href='%23s'%20y='-400'/%3e%3cg%20id='s5'%3e%3cuse%20xlink:href='%23s'%20transform='rotate(30)%20rotate(-30,0,200)'/%3e%3cuse%20xlink:href='%23s'%20transform='rotate(60)%20rotate(-60,0,200)'/%3e%3cuse%20xlink:href='%23s'%20transform='rotate(90)%20rotate(-90,0,200)'/%3e%3cuse%20xlink:href='%23s'%20transform='rotate(120)%20rotate(-120,0,200)'/%3e%3cuse%20xlink:href='%23s'%20transform='rotate(150)%20rotate(-150,0,200)'/%3e%3c/g%3e%3cuse%20xlink:href='%23s5'%20transform='scale(-1,1)'/%3e%3c/g%3e%3c/svg%3e)
[Horizon - Cancer] Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers
Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: Patients with refractory cancers and their caregivers/families will have access to optimised, tailored and affordable immunotherapeutic interventions that increase their quality of life, across European regions, EU Member States and Associated Countries; Healthcare professionals and academia will have access to clinical evidence, on effectiveness of immunotherapeutic interventions, to deploy evidence-based treatment interve…
Application window
Last round closed: 15 June 2026
What it funds
Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: Patients with refractory cancers and their caregivers/families will have access to optimised, tailored and affordable immunotherapeutic interventions that increase their quality of life, across European regions, EU Member States and Associated Countries; Healthcare professionals and academia will have access to clinical evidence, on effectiveness of immunotherapeutic interventions, to deploy evidence-based treatment interve…
Who it suits
Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: Patients with refractory cancers and their caregivers/families will have access to optimised, tailored and affordable immunothe…
- Life sciences & health
- Industrial R&D
Programme specifications
Expert guidance
We only put companies forward for competitions they can genuinely win. A free funding fit call will tell you where you stand against this programme.
Book a free consultationCheck your eligibilityMore from Horizon Europe & EU-wide
Applying for [Horizon - Cancer] Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers?
Talk to us about your grant funding plans and we will help you make it happen through effective, results-driven grant writing.
Book a free consultationFind the right grant, first time
Talk to us about your grant funding plans and we'll help you make it happen through effective, results-driven grant writing.